Le Lézard
Classified in: Science and technology
Subjects: PDT, PER

Egnyte Appoints New Data Protection Officer, Releases First GDPR eBook


Co-Founder Kris Lahiri takes on new role to ensure company-wide data compliance

BERKSHIRE, England, Oct. 19, 2017 /PRNewswire/ -- Egnyte, the leading cloud provider of smart content collaboration and governance, today announced the appointment of co-founder Kris Lahiri as their new Data Protection Officer (DPO). In Lahiri's new role he will be responsible for continuously monitoring Egnyte's regulatory compliance with the new General Data Protection Regulation (GDPR) and he will act as the main point of contact for the EU Commission during any audits or reviews.

"With so much more at stake under GDPR, we believe that all organisations should make the necessary moves to ensure complete compliance with the new rules and regulations, including appointing a DPO," said Kris Lahiri, Data Protection Officer and Co-Founder at Egnyte. "My team and I take tremendous pride in implementing proper procedures and protocols to ensure Egnyte's compliance with all regulations, not just the GDPR, and we will continue to make sure all of the data we handle is properly managed and secured."

Under the new GDPR, which will be implemented May 25, 2018, organisations will be held responsible for the proper handling of individuals' personal data. For Egnyte, who manages data across all 28 EU countries, GDPR compliance is critical to their business and customers.

Prior to Lahiri's appointment he served as Egnyte's Chief Information Security Officer, responsible for creating and implementing global information security strategies that protect all customers' content and users. Prior to Egnyte Lahiri spent many years leading the design and deployment of large-scale infrastructures for Fortune 100 customers Valdero and KPMG Consulting.

With just over six months until the GDPR is fully implemented, Egnyte also announced today the release of their first ever eBook, A Practical Guide to GDPR Compliance. The inaugural eBook is designed to help customers, partners and any other affected organisations ensure they are compliant under the new EU regulation.

To download a FREE copy of the eBook, A Practical Guide to GDPR Compliance, click here or visit our site.

About Egnyte

Egnyte transforms business through smarter content allowing organizations to connect, protect, and unlock value from all their content. Our Content Intelligence platform delivers smart content collaboration and governance in the cloud or on- premises to thousands of businesses around the world even the most regulated industries. Founded in 2007, Egnyte is privately held and headquartered in Mountain View, CA. Investors include venture capital firms, such as Google Ventures and Kleiner Perkins Caufield & Byers, as well as technology partners, such as CenturyLink and Seagate Technology.

Please visit www.egnyte.com or call 1-877- 7EGNYTE.

CONTACT: Colin Jordan, 1-650-743-6471, [email protected]

 


These press releases may also interest you

at 21:30
Rubrik, Inc. today announced the pricing of its upsized initial public offering of 23,500,000 shares of its Class A common stock at a public offering price of $32.00 per share. In addition, Rubrik has granted the underwriters a 30-day option to...

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:26
OKX, a leading Web3 technology company, has issued updates for April 24, 2024. OKX DeFi Launches 'zkSwap Bonus Event' Offering Users...

at 21:19
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on July 1, 2024 to shareholders of record at the close of business on June 1, 2024. The Board of Directors also declared the following...

at 21:02
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...



News published on and distributed by: